Company Description
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel.
It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson’s syndrome, and toxic epidermal necrolysis.
The company also provides contract development and manufacturing organization services to biotech companies.
It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Country | Israel |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Amir Reichman |
Contact Details
Address: Jerusalem BioPark, 2nd floor Jerusalem Israel | |
| Phone | 972 8 930 2529 |
| Website | scinai.com |
Stock Details
| Ticker Symbol | SCNI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611747 |
| CUSIP Number | 09073Q204 |
| ISIN Number | US09073Q2049 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Amir Reichman M.B.A., M.Sc. | Chief Executive Officer and Director |
| Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Dr. Dalit Weinstein Fischer Ph.D. | Chief Technology Officer |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist |
| Merav Kamensky | Head of Quality Control |
| Dr. Naama Adi Hen | Head of Quality Asurance |
| Alona Tal | Head of Business Administration |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2025 | 6-K | Report of foreign issuer |
| Jun 5, 2025 | 424B3 | Prospectus |
| Jun 5, 2025 | 6-K | Report of foreign issuer |
| Jun 2, 2025 | 6-K | Report of foreign issuer |
| May 15, 2025 | EFFECT | Notice of Effectiveness |
| May 12, 2025 | POS AM | Post-Effective amendments for registration statement |
| May 7, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Apr 29, 2025 | NT 20-F | Notification of inability to timely file Form 20-F |
| Mar 27, 2025 | 6-K | Report of foreign issuer |
| Mar 26, 2025 | SCHEDULE 13G | Filing |